Multiple randomized controlled trials (RCTs) assessing real-time continuous glucose monitoring (rtCGM) or flash glucose monitoring (FGM) have demonstrated an effect on reducing glycated hemoglobin (HbA1c) levels and/or rates of hypoglycemia in patients with diabetes using intensive insulin regimens (multiple daily injections [MDI] or continuous subcutaneous insulin infusion [CSII]) (1–3). The gene discussed is INS; the disease is diabetes mellitus.